The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients
| Autor: | Yesim Parman, Vuslat Yilmaz, Güher Saruhan-Direskeneli, Hacer Durmus, Piraye Oflazer, Fikret Aysal, Erdem Tüzün, Ozlem Gungor-Tuncer, Feza Deymeer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male Adolescent medicine.medical_treatment Immunology CD38 CD19 03 medical and health sciences Young Adult 0302 clinical medicine Myasthenia Gravis medicine Immunology and Allergy Humans B-cell activating factor Child B cell Aged B-Lymphocytes biology business.industry Immunosuppression Middle Aged medicine.disease Myasthenia gravis Pathophysiology 030104 developmental biology medicine.anatomical_structure Treatment Outcome Neurology biology.protein Female Neurology (clinical) Antibody business 030217 neurology & neurosurgery Biomarkers Immunosuppressive Agents |
| Zdroj: | Journal of neuroimmunology. 349 |
| ISSN: | 1872-8421 |
| Popis: | B cells play a major role in the pathophysiology of myasthenia gravis (MG) with their ability to produce disease specific, pathogenic antibodies. However, their status during disease development and follow-up stages of the disease in the peripheral blood may need further studies to determine useful markers. In this study, we aimed to detect B cell associated factors concerning immunosuppressive treatment in generalized non-thymomatous MG patients. Although CD19(+) B cell distribution did not vary among disease subgroups, expressions of both CD38 and BAFFR were altered on B cells in MG patients under immunosuppressive therapy. Serum levels of BAFF were elevated in untreated MG patients as compared to treated MG patients and healthy controls. B cell activation factors may show profound alterations due to immunosuppression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect